Coronavirus Disease 2019 Clinical Trial
Official title:
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV, & COVID-19 and LIAISON PLEX Respiratory (RSP) Flex Assays in Symptomatic Patients in Australia
To establish the relative accuracy of the LIAISON® NES Flu A/B, RSV & COVID-19 assay for viral nucleic acid targets from professionally collected or patient self-collected dry nasal (NS) swabs and to establish the relative accuracy of the LIAISON PLEX® RSP Flex assay from NS and nasopharyngeal swabs (NPS) in applicable transport media from human patients exhibiting clinical signs and symptoms of a respiratory tract infection.
This study is a clinical evaluation of two investigational devices on the same patient specimens: - The LIAISON® NES FLU A/B, RSV & COVID-19 assay used for the detection and identification of influenza A, influenza B, RSV and SARS-CoV-2 on the LIAISON® NES system, developed by DiaSorin Molecular - The LIAISON PLEX® RSP Flex assay used for the detection and identification of 19 common respiratory pathogens, including 14 viral and 5 bacterial targets on the LIAISON PLEX® system, developed by Luminex Corporation (a subsidiary of DiaSorin) This study will utilize untrained operators to perform investigational device testing on the LIAISON NES platform, and as such instrument or assay-specific training will not be provided beforehand. Sites will receive the necessary protocols and instructions for use required to implement the study protocol. Testing on the LIAISON PLEX® platform will be performed by trained operators. Study staff will receive training on the device prior to the start of testing. The diagnostic accuracy of the LIAISON® NES FLU A/B, RSV & COVID-19 assay will be evaluated using dry NS specimens prospectively collected from patients who meet the study inclusion criteria. The diagnostic accuracy of the LIAISON PLEX® RSP Flex assay will be evaluated using NS and NPS specimens prospectively collected from patients who meet the study inclusion criteria and stored in the applicable transport media. Performance of the LIAISON® NES FLU A/B, RSV & COVID-19 and LIAISON PLEX® RSP Flex assays will be compared to one or more US FDA-cleared molecular assays, or as required by the local regulatory body. Approximately 600-1000 prospective specimens will be tested using the LIAISON® NES FLU A/B, RSV & COVID-19 and LIAISON PLEX® RSP Flex assays, with a goal to obtain approximately 50 comparator method confirmed positives per target for influenza A and SARS CoV-2 and 30 comparator method confirmed positives per target for influenza B and RSV. The study is estimated to be conducted for approximately 3 months and should cover the length of the flu season, as appropriate. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05091411 -
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
|
Phase 3 | |
| Completed |
NCT05107375 -
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
|
Phase 3 | |
| Active, not recruiting |
NCT05128643 -
Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)
|
Phase 3 | |
| Completed |
NCT04988217 -
Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)
|
Phase 1/Phase 2 | |
| Completed |
NCT04579393 -
Fostamatinib for Hospitalized Adults With COVID-19
|
Phase 2 | |
| Withdrawn |
NCT04390217 -
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
|
Phase 2 | |
| Recruiting |
NCT05047783 -
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
|
Phase 2 | |
| Completed |
NCT04646044 -
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
|
Phase 1 | |
| Recruiting |
NCT05092568 -
Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
|
||
| Completed |
NCT05364268 -
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
|
||
| Completed |
NCT06189040 -
Immunogenicity After COVID-19 Vaccines in Adapted Schedules
|
Phase 4 | |
| Recruiting |
NCT04401436 -
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
|
||
| Not yet recruiting |
NCT04395742 -
1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
|
||
| Recruiting |
NCT04388631 -
Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
|
||
| Completed |
NCT05501288 -
Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019
|
N/A | |
| Active, not recruiting |
NCT05216471 -
Identify Coronavirus Disease by Chest X-ray
|
||
| Terminated |
NCT04672564 -
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
|
Phase 3 | |
| Completed |
NCT04967781 -
Autoimmunity Contributes to the Severe Progression of COVID-19
|
||
| Completed |
NCT04678830 -
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
|
Phase 2 | |
| Completed |
NCT04497194 -
Registry of COVID-19 Patients at AOUI Verona
|